Mark Milner, MD
Ophthalmology · Palm Beach Gardens, FLNPI 1932171147
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $737,678 of the $1,217,463 with a category attached, or 60.6%. 31 manufacturers reported payments, led by AbbVie at 24.2% of the total. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,358 payments — averaging $896.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$295K
- Bausch & Lomb Americas Inc.$188K
- Tarsus Pharmaceuticals, Inc.$145K
- Sun Pharmaceutical Industries Inc.$114K
- Eyevance Pharmaceuticals LLC$110K
- Oyster Point Pharma, Inc.$105K
- plus $259K from 25 others
What the payments were for
- Consulting fees$362,72030%
- Speaking & faculty fees$737,67861%
- Travel & lodging$80,3617%
- Food & beverage$36,5193%
- Education$1860%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 332 | $295,101 |
| Bausch & Lomb Americas Inc. | 167 | $187,873 |
| Tarsus Pharmaceuticals, Inc. | 84 | $145,469 |
| Sun Pharmaceutical Industries Inc. | 144 | $114,142 |
| Eyevance Pharmaceuticals LLC | 96 | $109,979 |
| Oyster Point Pharma, Inc. | 109 | $105,497 |
| Biotissue Holdings Inc. | 57 | $98,192 |
| Alcon | 59 | $63,321 |
| Dompe US, Inc. | 49 | $38,106 |
| Novartis | 56 | $15,619 |
| Shire North American Group Inc | 22 | $15,104 |
| Alcon Research LLC | 5 | $13,000 |
| Thea Pharma Inc. | 3 | $7,403 |
| Tearlab Corp | 7 | $2,169 |
| Mallinckrodt Hospital Products Inc. | 56 | $1,510 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $1,370 |
| Glaukos Corporation | 27 | $1,051 |
| Harrow Eye, LLC | 18 | $788 |
| Johnson & Johnson Surgical Vision, Inc. | 12 | $597 |
| Rayner Intraocular Lenses Limited | 11 | $319 |
| ANI Pharmaceuticals, Inc. | 8 | $173 |
| Kala Pharmaceuticals, Inc. | 8 | $163 |
| Sight Sciences, Inc. | 3 | $162 |
| Amgen(2 entities) | 4 | $80 |
| NEW World Medical,inc. | 3 | $77 |
| Rxsight Inc | 3 | $60 |
| Ocular Therapeutix, Inc. | 2 | $42 |
| Aerie Pharmaceuticals, Inc. | 2 | $32 |
| Mallinckrodt Enterprises LLC | 1 | $26 |
| Omeros Corporation | 1 | $19 |
| Apellis Pharmaceuticals, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIIDRA$186,079
- MIEBO$163,874
- XDEMVY$143,337
- RESTASIS$142,166
- CEQUA$112,265
- TYRVAYA$102,118
- TRYPTYR$61,933
- RESTASIS MULTIDOSE$56,920
- Prokera$56,216
- AmnioGraft$50,514
- AmnioGuard$43,940
- Flarex$42,751
- Zerviate$36,861
- Oxervate$35,237
- Tobradex ST$29,578
- VUITY$17,945
- DURYSTA$3,225
- TearLab Osmolarity System$1,900
- LOTEMAX SM$1,111
- BLINK NUTRITEARS$850
How this compares
$1,217,463 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 605 | $470,160 |
| OxervateCenegermin-Bkbj | 16 | $449,972 |
| XdemvyLotilaner | 75 | $135,620 |
| MieboPerfluorohexyloctane/Pf | 151 | $121,566 |
| XiidraLifitegrast | 133 | $119,363 |
| CequaCyclosporine | 111 | $77,980 |
| Cyclosporine | 108 | $37,478 |
| TyrvayaVarenicline Tartrate | 51 | $32,327 |
| ZirganGanciclovir | 52 | $24,042 |
| Prednisolone Acetate | 474 | $22,678 |
| LumiganBimatoprost | 32 | $15,530 |
| ErythromycinErythromycin Base | 980 | $10,240 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 200 | $9,869 |
| FlarexFluorometholone Acetate | 62 | $8,576 |
| RocklatanNetarsudil Mesylat/Latanoprost | 12 | $7,558 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $295,101 | $497,188673 claims |
| Dompe US, Inc.Oxervate | $38,106 | $449,97216 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra, Zirgan | $187,873 | $264,971336 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $145,469 | $135,62075 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $114,142 | $77,980111 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $105,497 | $32,32751 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $32 | $13,57129 claims |
| Eyevance Pharmaceuticals LLCFlarex | $109,979 | $8,57662 claims |
| AlconSimbrinza | $63,321 | $5,27318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Palm Beach Gardens
- Jorge FortunPalm Beach Gardens$798K
- Larissa CamejoPalm Beach Gardens$244K
- David GoldmanPalm Beach Gardens$239K
- Clifford SalingerPalm Beach Gardens$163K
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Neel DesaiLargo$1M
- Courtney BoveeTampa$796K
- Harold BrooksTallahassee$683K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.